Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci181671 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Tingting Qin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Azacitidine, Epigenesis, Genetic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND Immune checkpoint blockade (ICB) is an effective treatment in a subset of patients diagnosed with head and neck squamous cell carcinoma (HNSCC); however, the majority of patients are refractory. METHODS In a nonrandomized, open-label Phase 1b clinical trial, participants with recurrent and/or metastatic (R/M) HNSCC were treated with low-dose 5-azacytidine (5-aza) daily for either 5 or 10 days in combination with durvalumab and tremelimumab after progression on ICB. The primary objective was to assess the biologically effective dose of 5-aza as determined by molecular changes in paired baseline and on-treatment tumor biopsies; the secondary objective was safety. RESULTS Thirty-eight percent (3 of 8) of participants with evaluable paired tissue samples had a greater-than 2-fold increase from baseline in IFN-γ signature and CD274 (programmed cell death protein 1 ligand, PD-L1) expression within the tumor microenvironment (TME), which was associated with increased CD8 + T cell infiltration and decreased infiltration of CD4 + T regulatory cells. The mean neutrophil-to-lymphocyte ratio (NLR) decreased by greater than 50%, from 14.2 (SD 22.6) to 6.9 (SD 5.2). Median overall survival (OS) was 16.3 months (95% CI 1.9, NA), 2-year OS rate was 24.7% (95% CI: 4.5%, 53.2%), and 58% (7 of 12) of treated participants demonstrated prolonged OS of greater than 12 months. CONCLUSION Our findings suggest that low-dose 5-aza can reprogram systemic host immune responses and the local TME to increase IFN-γ and PD-L1 expression. The increased expression of these established biomarkers correlated with prolonged OS upon ICB rechallenge. TRIAL REGISTRATION ClinicalTrials.gov NCT03019003. FUNDING NIH/NCI P01 CA240239.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Surgery, and.
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
- AstraZeneca
- National Cancer Institute
Zitieren
APA
Qin, T., Mattox, A. K., Campbell, J. S., Park, J. C., Shin, K. Y., Li, S., Sadow, P. M., Faquin, W. C., Micevic, G., Daniels, A. J., Haddad, R., Garris, C. S., Pittet, M. J., Mempel, T. R., ONeill, A., Sartor, M. A., & Pai, S. I. (2025). Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal of Clinical Investigation. https://doi.org/10.1172/jci181671
Vancouver
Qin T, Mattox AK, Campbell JS, Park JC, Shin KY, Li S, et al. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal of Clinical Investigation. 2025. doi:10.1172/jci181671
BibTeX
@article{Qin2025,
author = {Qin, Tingting and Mattox, Austin K and Campbell, Jean S and Park, Jong Chul and Shin, Kee-Young and Li, Shiting and Sadow, Peter M and Faquin, William C and Micevic, Goran and Daniels, Andrew J and Haddad, Robert and Garris, Christopher S and Pittet, Mikael J and Mempel, Thorsten R and ONeill, Anne and Sartor, Maureen A and Pai, Sara I},
title = {Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci181671}
}
EUVIMED